Bioniz reports Phase I safety data for BNZ-1

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a Phase I trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1 were well tolerated with no serious adverse events or dose-limiting toxicities (DLTs) reported. Data were presented at the American Society of Hematology meeting in Atlanta in December 2017.

Subjects in the open-label, U.S. trial received a single dose of 0.2, 0.4 , 0.8, 1.6, 3.2 or 6.4 mg/kg IV BNZ-1...